Chronic Spontaneous Urticaria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceutic

Chronic Spontaneous Urticaria Pipeline constitutes 20+ key companies continuously working towards developing 20+ Chronic Spontaneous Urticaria treatment therapies, analyzes DelveInsight.

Chronic Spontaneous Urticaria Overview:

Urticaria, also known as hives, wheals, or nettle rash, is characterized by itchy, red, and swollen wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that persist for six weeks or longer, occurring on most days of the week. It is marked by the presence of wheals and angioedema, which can appear anywhere on the body and are typically widespread.

Diagnosis of chronic urticaria is based on a history of daily or episodic wheals lasting less than 24 hours over a period exceeding six weeks, without any identifiable physical triggers. International guidelines recommend limiting diagnostic tests to a differential blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) to rule out other conditions.

Treatment options for chronic spontaneous urticaria include antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.

Request for a detailed insights report on Chronic Spontaneous Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Chronic Spontaneous Urticaria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Spontaneous Urticaria Therapeutics Market.

Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report

DelveInsight's Chronic Spontaneous Urticaria pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Spontaneous Urticaria treatment.
Key Chronic Spontaneous Urticaria companies such as United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others are evaluating new drugs for Chronic Spontaneous Urticaria to improve the treatment landscape.
Promising Chronic Spontaneous Urticaria pipeline therapies in various stages of development include Dupilumab, Tezepelumab, Barzolvolimab, and others.

Recent breakthroughs in the Chronic Spontaneous Urticaria Pipeline Segment:

In February 2025, Allakos announced the discontinuation of its AK006 program for treating chronic hives after a 14-week clinical trial involving 34 patients showed no significant efficacy over placebo. This outcome led the company to lay off approximately 75% of its workforce and explore strategic alternatives, including potential mergers or partnerships.
In November 2025, the U.S. Food and Drug Administration (FDA) accepted the resubmission of the sBLA for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with CSU inadequately controlled with H1 antihistamines. This decision was supported by data from the LIBERTY-CUPID Phase 3 clinical program, particularly Study C, which demonstrated that Dupixent significantly reduced itch and hive activity compared to baseline. The FDA's target action date for this application is April 18, 2025.

Chronic Spontaneous Urticaria Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Chronic Spontaneous Urticaria Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Spontaneous Urticaria market.

Download our free sample page report on Chronic Spontaneous Urticaria pipeline insights @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Chronic Spontaneous Urticaria Emerging Drugs

Dupilumab: Sanofi
Tezepelumab: Amgen
Barzolvolimab: Celldex Therapeutics

Chronic Spontaneous Urticaria Companies

More than 20 key companies are actively developing therapies for Chronic Spontaneous Urticaria. Among them, Sanofi has a drug candidate in the most advanced stage of development, currently in the preregistration phase.

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic Spontaneous Urticaria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Spontaneous Urticaria Therapies and Key Companies: Chronic Spontaneous Urticaria Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Spontaneous Urticaria Pipeline Therapeutic Assessment
• Chronic Spontaneous Urticaria Assessment by Product Type
• Chronic Spontaneous Urticaria By Stage
• Chronic Spontaneous Urticaria Assessment by Route of Administration
• Chronic Spontaneous Urticaria Assessment by Molecule Type

Download Chronic Spontaneous Urticaria Sample report to know in detail about the Chronic Spontaneous Urticaria treatment market @ Chronic Spontaneous Urticaria Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Chronic Spontaneous Urticaria Current Treatment Patterns
4. Chronic Spontaneous Urticaria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Spontaneous Urticaria Late-Stage Products (Phase-III)
7. Chronic Spontaneous Urticaria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Spontaneous Urticaria Discontinued Products
13. Chronic Spontaneous Urticaria Product Profiles
14. Chronic Spontaneous Urticaria Key Companies
15. Chronic Spontaneous Urticaria Key Products
16. Dormant and Discontinued Products
17. Chronic Spontaneous Urticaria Unmet Needs
18. Chronic Spontaneous Urticaria Future Perspectives
19. Chronic Spontaneous Urticaria Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Spontaneous Urticaria Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.